Compare Adaptive Biotechnologies Corp (ADPT) vs Sprott Uranium Miners ETF (URNM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Sprott Uranium Miners ETF — how do they compare? Adaptive Biotechnologies Corp trades at $20.12 (market cap $3.33B), while Sprott Uranium Miners ETF trades at $51. The key difference: Adaptive Biotechnologies Corp is trading nearer its 52-week high, Sprott Uranium Miners ETF nearer its low. Which is the better fit depends on your goals.
| ADPT | URNM | |
|---|---|---|
Market Cap | $3.33B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $22.37 | $83.99 |
52-Week Low | $10.24 | $44.14 |
Enterprise Value | $3.19B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
URNM trades at $53.56, up 1.38% today, but technical indicators signal a bearish trend with moving averages showing strong sell signals. The ETF is positioned at the intersection of AI-driven electricity demand and nuclear energy growth, with recent news highlighting uranium's role in powering data centers. Key support lies at $52, while resistance is near $54.
Outlook is mixed: long-term growth is supported by nuclear energy demand, but short-term risks include volatility in uranium prices and miner equity valuations. Investment opportunity hinges on the AI power narrative, yet caution is warranted due to technical weakness and concentrated miner exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Sprott Uranium Miners ETF
URNM is a pure-play ETF that invests in the global uranium industry. It provides exposure to companies involved in the mining, exploration, and production of uranium, as well as physical uranium holdings, with top assets like Cameco, Uranium Energy Corp, and the Sprott Physical Uranium Trust.
Read more on URNM →
